{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:19:37Z","timestamp":1792120777992,"version":"4.4.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T00:00:00Z","timestamp":1764374400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004622","name":"Dutch Cancer Society","doi-asserted-by":"publisher","award":["10351"],"award-info":[{"award-number":["10351"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jtct.2025.11.039","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T16:10:28Z","timestamp":1764432628000},"page":"452.e1-452.e18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Decitabine Conditioning Improves Natural Killer Cell Maturation and Limits CD8+ T Cell Terminal Differentiation Post-Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia Patients"],"prefix":"10.1016","volume":"32","author":[{"given":"Jesper","family":"van Eck van der Sluijs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7273-4896","authenticated-orcid":false,"given":"Diede","family":"van Ens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayla","family":"Grotens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2667-5572","authenticated-orcid":false,"given":"Esther","family":"Fern\u00e1ndez Merino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6292-0165","authenticated-orcid":false,"given":"Nadia","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1155-6749","authenticated-orcid":false,"given":"Daan","family":"Heister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresia N.","family":"Scheele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2795-1194","authenticated-orcid":false,"given":"Chrysanthi","family":"Kagiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaas P.M.","family":"Schaap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter J.F.M.","family":"van der Velden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"van Dorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerwin","family":"Huls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joop H.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3581-4816","authenticated-orcid":false,"given":"Jolanda","family":"Brummelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anniek B.","family":"van der Waart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Dolstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willemijn","family":"Hobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jtct.2025.11.039_bib0001","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3324\/haematol.10867","article-title":"Current status of reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia","volume":"92","author":"Blaise","year":"2007","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.jtct.2025.11.039_bib0002","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/CCO.0b013e328342b82a","article-title":"Reduced- intensity versus myeloablative allogeneic stem cell transplantation for the treatment of acute myeloid leukemia, myelodysplastic syndrome and acute lymphoid leukemia","volume":"23","author":"Horwitz","year":"2011","journal-title":"Curr Opin Oncol"},{"issue":"15","key":"10.1016\/j.jtct.2025.11.039_bib0003","first-page":"3730","article-title":"Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia","volume":"59","author":"Melki","year":"1999","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.jtct.2025.11.039_bib0004","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1182\/blood-2008-01-128595","article-title":"DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication","volume":"112","author":"Whitman","year":"2008","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.jtct.2025.11.039_bib0005","doi-asserted-by":"crossref","first-page":"7473","DOI":"10.1073\/pnas.1002650107","article-title":"Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine","volume":"107","author":"Blum","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.jtct.2025.11.039_bib0006","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3324\/haematol.2011.048231","article-title":"A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy","volume":"97","author":"L\u00fcbbert","year":"2012","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.jtct.2025.11.039_bib0007","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.2009.23.9178","article-title":"Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia","volume":"28","author":"Cashen","year":"2010","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.jtct.2025.11.039_bib0008","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jtct.2025.11.039_bib0009","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1007\/s12325-021-01948-8","article-title":"The clinical value of decitabine monotherapy in patients with acute myeloid leukemia","volume":"39","author":"Santini","year":"2022","journal-title":"Adv Ther"},{"issue":"2","key":"10.1016\/j.jtct.2025.11.039_bib0010","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1080\/17843286.2019.1665233","article-title":"Real-world data confirming the efficacy and safety of decitabine in acute myeloid leukaemia: results from a retrospective Belgian registry study","volume":"76","author":"Meers","year":"2021","journal-title":"Acta Clin Belg"},{"issue":"4","key":"10.1016\/j.jtct.2025.11.039_bib0011","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/hon.2663","article-title":"Real-world experience with decitabine as a first-line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy","volume":"37","author":"Bocchia","year":"2019","journal-title":"Hematol Oncol"},{"issue":"8","key":"10.1016\/j.jtct.2025.11.039_bib0012","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1186\/s13059-014-0406-2","article-title":"DNMT inhibitors reverse a specific signature of aberrant promoter DNA methylation and associated gene silencing in AML","volume":"15","author":"Lund","year":"2014","journal-title":"Genome Biol"},{"key":"10.1016\/j.jtct.2025.11.039_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.624742","article-title":"Hypomethylating agents and immunotherapy: therapeutic synergism in acute myeloid leukemia and myelodysplastic syndromes","volume":"11","author":"Wong","year":"2021","journal-title":"Front Oncol"},{"issue":"22","key":"10.1016\/j.jtct.2025.11.039_bib0014","doi-asserted-by":"crossref","first-page":"14042","DOI":"10.3390\/ijms232214042","article-title":"Decitabine treatment induces a viral mimicry response in cervical cancer cells and further sensitizes cells to chemotherapy","volume":"23","author":"Alexandraki","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.jtct.2025.11.039_bib0015","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/gene.2014.58","article-title":"Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia","volume":"16","author":"Baraga\u00f1o Raneros","year":"2015","journal-title":"Genes Immun"},{"issue":"2","key":"10.1016\/j.jtct.2025.11.039_bib0016","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1182\/blood-2017-06-790204","article-title":"Decitabine enhances targeting of AML cells by CD34(+) progenitor-derived NK cells in NOD\/SCID\/IL2Rg(null) mice","volume":"131","author":"Cany","year":"2018","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jtct.2025.11.039_bib0017","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1158\/1078-0432.CCR-06-3091","article-title":"Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2\u2032-deoxycytidine in cutaneous melanoma: immunotherapeutic implications","volume":"13","author":"Fonsatti","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.jtct.2025.11.039_bib0018","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.leukres.2007.02.020","article-title":"Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis","volume":"31","author":"Rohner","year":"2007","journal-title":"Leuk Res"},{"key":"10.1016\/j.jtct.2025.11.039_bib0019","doi-asserted-by":"crossref","first-page":"32470","DOI":"10.1038\/srep32470","article-title":"Combination treatment with decitabine and ionizing radiation enhances tumor cells susceptibility of T cells","volume":"6","author":"Son","year":"2016","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.jtct.2025.11.039_bib0020","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00262-016-1868-8","article-title":"DNA methyltransferase inhibition increases efficacy of adoptive cellular immunotherapy of murine breast cancer","volume":"65","author":"Terracina","year":"2016","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"10.1016\/j.jtct.2025.11.039_bib0021","first-page":"454","article-title":"Decitabine treatment sensitizes tumor cells to T-cell-mediated cytotoxicity in patients with myelodysplastic syndromes","volume":"9","author":"Zhang","year":"2017","journal-title":"Am J Transl Res"},{"issue":"2","key":"10.1016\/j.jtct.2025.11.039_bib0022","doi-asserted-by":"crossref","first-page":"462","DOI":"10.3390\/cancers12020462","article-title":"Decitabine augments chemotherapy-induced PD-L1 upregulation for PD-L1 blockade in colorectal cancer","volume":"12","author":"Huang","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.jtct.2025.11.039_bib0023","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/leu.2013.355","article-title":"Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents","volume":"28","author":"Yang","year":"2014","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.jtct.2025.11.039_bib0024","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.bbmt.2016.02.003","article-title":"Addition of 10-day decitabine to fludarabine\/total body irradiation conditioning is feasible and induces tumor-associated antigen-specific T cell responses","volume":"22","author":"Cruijsen","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2025.11.039_bib0025","doi-asserted-by":"crossref","first-page":"5753","DOI":"10.1007\/s13277-014-1764-9","article-title":"Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1","volume":"35","author":"Krishnadas","year":"2014","journal-title":"Tumour Biol"},{"issue":"12","key":"10.1016\/j.jtct.2025.11.039_bib0026","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1093\/neuonc\/noac107","article-title":"Decitabine increases neoantigen and cancer testis antigen expression to enhance T-cell-mediated toxicity against glioblastoma","volume":"24","author":"Ma","year":"2022","journal-title":"Neuro Oncol"},{"issue":"11","key":"10.1016\/j.jtct.2025.11.039_bib0027","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1182\/blood-2009-11-249474","article-title":"Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia","volume":"116","author":"Goodyear","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2025.11.039_bib0028","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.bbmt.2015.09.004","article-title":"Tolerability and clinical activity of post-transplantation azacitidine in patients allografted for acute myeloid leukemia treated on the RICAZA trial","volume":"22","author":"Craddock","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2025.11.039_bib0029","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-17-1792","article-title":"NY-ESO-1 Vaccination in combination with decitabine induces antigen-specific T-lymphocyte responses in patients with myelodysplastic syndrome","volume":"24","author":"Griffiths","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jtct.2025.11.039_bib0030","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/blood-2009-12-257253","article-title":"In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia","volume":"116","author":"Choi","year":"2010","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.jtct.2025.11.039_bib0031","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1182\/blood-2011-09-377044","article-title":"Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)","volume":"119","author":"Goodyear","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.11.039_bib0032","article-title":"Low-dose decitabine augments the activation and anti-tumor immune response of IFN- \u0393(+) CD4(+) T cells through enhancing I\u03baB\u03b1 degradation and NF-\u03baB activation","volume":"9","author":"Li","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"7","key":"10.1016\/j.jtct.2025.11.039_bib0033","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.molcel.2021.01.038","article-title":"DNA hypomethylating agents increase activation and cytolytic activity of CD8(+) T cells","volume":"81","author":"Loo Yau","year":"2021","journal-title":"Mol Cell"},{"issue":"5","key":"10.1016\/j.jtct.2025.11.039_bib0034","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/bjh.16228","article-title":"Multi-dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML","volume":"188","author":"Zhao","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2025.11.039_bib0035","article-title":"Concentration-dependent decitabine effects on primary NK cells viability, phenotype, and function in the absence of obvious NK cells proliferation-original article","volume":"12","author":"Li","year":"2021","journal-title":"Front Pharmacol"},{"issue":"7","key":"10.1016\/j.jtct.2025.11.039_bib0036","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/cyto.a.22625","article-title":"FlowSOM: Using self-organizing maps for visualization and interpretation of cytometry data","volume":"87","author":"Van Gassen","year":"2015","journal-title":"Cytometry A"},{"issue":"7","key":"10.1016\/j.jtct.2025.11.039_bib0037","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.bbmt.2009.01.019","article-title":"Natural killer cells in allogeneic transplantation: effect on engraftment, graft- versus-tumor, and graft-versus-host responses","volume":"15","author":"Gill","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2025.11.039_bib0038","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.it.2018.04.009","article-title":"NK Cells mediate a crucial graft-versus-leukemia effect in haploidentical-HSCT to cure high-risk acute leukemia","volume":"39","author":"Locatelli","year":"2018","journal-title":"Trends Immunol"},{"issue":"7","key":"10.1016\/j.jtct.2025.11.039_bib0039","doi-asserted-by":"crossref","first-page":"giy083","DOI":"10.1093\/gigascience\/giy083","article-title":"Clustering trees: a visualization for evaluating clusterings at multiple resolutions","volume":"7","author":"Zappia","year":"2018","journal-title":"Gigascience"},{"key":"10.1016\/j.jtct.2025.11.039_bib0040","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.3389\/fimmu.2019.02357","article-title":"Natural killer cells in myeloid malignancies: immune surveillance, NK cell dysfunction, and pharmacological opportunities to bolster the endogenous NK cells","volume":"10","author":"Carlsten","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtct.2025.11.039_bib0041","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3389\/fimmu.2017.00573","article-title":"Natural killer defective maturation is associated with adverse clinical outcome in patients with acute myeloid leukemia","volume":"8","author":"Chretien","year":"2017","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jtct.2025.11.039_bib0042","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7150\/jca.5049","article-title":"Clinical relevance of natural killer cells following hematopoietic stem cell transplantation","volume":"4","author":"Palmer","year":"2013","journal-title":"J Cancer"},{"issue":"7","key":"10.1016\/j.jtct.2025.11.039_bib0043","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.3390\/cancers12071974","article-title":"Reconstitution of T cell subsets following allogeneic hematopoietic cell transplantation","volume":"12","author":"Dekker","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.jtct.2025.11.039_bib0044","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/sctm.18-0248","article-title":"Concise review: Boosting T-cell reconstitution following allogeneic transplantation-current concepts and future perspectives","volume":"8","author":"Simons","year":"2019","journal-title":"Stem Cells Transl Med"},{"issue":"12","key":"10.1016\/j.jtct.2025.11.039_bib0045","doi-asserted-by":"crossref","first-page":"e50896","DOI":"10.1371\/journal.pone.0050896","article-title":"Decreased levels of circulating IL17-producing CD161+CCR6+ T cells are associated with graft-versus-host disease after allogeneic stem cell transplantation","volume":"7","author":"van der Waart","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jtct.2025.11.039_bib0046","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2020.595395","article-title":"Epigenetic therapy promotes the ratio of Th1\/Th17 lineage to reverse immune evasion and treat leukemia relapse post-allogeneic stem cell transplantation in non-APL AML patients","volume":"7","author":"Xi","year":"2021","journal-title":"Front Mol Biosci"},{"issue":"8","key":"10.1016\/j.jtct.2025.11.039_bib0047","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/cas.12459","article-title":"Th17 cells and interleukin-17 increase with poor prognosis in patients with acute myeloid leukemia","volume":"105","author":"Han","year":"2014","journal-title":"Cancer Sci"},{"issue":"1","key":"10.1016\/j.jtct.2025.11.039_bib0048","doi-asserted-by":"crossref","first-page":"39","DOI":"10.4049\/jimmunol.1102807","article-title":"B and T lymphocyte attenuator mediates inhibition of tumor-reactive CD8+ T cells in patients after allogeneic stem cell transplantation","volume":"189","author":"Hobo","year":"2012","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.jtct.2025.11.039_bib0049","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.bbmt.2017.11.027","article-title":"Increased coexpression of PD-1, TIGIT, and KLRG-1 on tumor-reactive CD8(+) T cells during relapse after allogeneic stem cell transplantation","volume":"24","author":"Hutten","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.11.039_bib0050","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3389\/fimmu.2013.00455","article-title":"Inhibitory receptor expression depends more dominantly on differentiation and activation than \"Exhaustion\" of human CD8 T cells","volume":"4","author":"Legat","year":"2013","journal-title":"Front Immunol."},{"issue":"12","key":"10.1016\/j.jtct.2025.11.039_bib0051","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.it.2016.09.002","article-title":"Senescence of T lymphocytes: implications for enhancing human immunity","volume":"37","author":"Akbar","year":"2016","journal-title":"Trends Immunol"},{"issue":"1","key":"10.1016\/j.jtct.2025.11.039_bib0052","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000639","article-title":"CD8(+)CD57(+) T cells exhibit distinct features in human non-small cell lung cancer","volume":"8","author":"Huang","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"21","key":"10.1016\/j.jtct.2025.11.039_bib0053","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.120974","article-title":"Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy","volume":"3","author":"Knaus","year":"2018","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/j.jtct.2025.11.039_bib0054","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/ajco.13304","article-title":"Increasing Tim-3+CD244+, Tim-3+CD57+, and Tim-3+PD-1+ T cells in patients with acute myeloid leukemia","volume":"16","author":"Tan","year":"2020","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.jtct.2025.11.039_bib0055","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.699895","article-title":"TIGIT, the next step towards successful combination immune checkpoint therapy in cancer","volume":"12","author":"Ge","year":"2021","journal-title":"Front Immunol"},{"issue":"16","key":"10.1016\/j.jtct.2025.11.039_bib0056","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1182\/blood-2018-01-825265","article-title":"TIGIT immune checkpoint blockade restores CD8(+) T-cell immunity against multiple myeloma","volume":"132","author":"Guillerey","year":"2018","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jtct.2025.11.039_bib0057","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1158\/1078-0432.CCR-15-2626","article-title":"T-cell immunoglobulin and ITIM domain (TIGIT) associates with CD8+ T-cell exhaustion and poor clinical outcome in AML patients","volume":"22","author":"Kong","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.jtct.2025.11.039_bib0058","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1007\/s00262-021-02886-8","article-title":"TIGIT promotes CD8(+)T cells exhaustion and predicts poor prognosis of colorectal cancer","volume":"70","author":"Liang","year":"2021","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.jtct.2025.11.039_bib0059","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12967-022-03480-x","article-title":"Blocking TIGIT\/CD155 signalling reverses CD8(+) T cell exhaustion and enhances the antitumor activity in cervical cancer","volume":"20","author":"Liu","year":"2022","journal-title":"J Transl Med"},{"issue":"33","key":"10.1016\/j.jtct.2025.11.039_bib0060","doi-asserted-by":"crossref","first-page":"14733","DOI":"10.1073\/pnas.1009731107","article-title":"Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection","volume":"107","author":"Jin","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.jtct.2025.11.039_bib0061","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.jtct.2025.11.039_bib0062","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol"},{"issue":"8","key":"10.1016\/j.jtct.2025.11.039_bib0063","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jtct.2025.11.039_bib0064","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.exphem.2022.04.002","article-title":"Recurrent transcriptional responses in AML and MDS patients treated with decitabine","volume":"111","author":"Upadhyay","year":"2022","journal-title":"Exp Hematol"},{"issue":"23","key":"10.1016\/j.jtct.2025.11.039_bib0065","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1182\/bloodadvances.2018022053","article-title":"Direct modulation of the bone marrow mesenchymal stromal cell compartment by azacitidine enhances healthy hematopoiesis","volume":"2","author":"Wenk","year":"2018","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.jtct.2025.11.039_bib0066","first-page":"2462","article-title":"Effect of decitabine and thalidomide on the immunological effect and bone marrow mesenchymal stem cells of patients with myelodysplastic syndrome","volume":"13","author":"Xing","year":"2021","journal-title":"Am J Transl Res"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672501615X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672501615X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T19:34:37Z","timestamp":1778355277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266663672501615X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":66,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S266663672501615X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.11.039","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Decitabine Conditioning Improves Natural Killer Cell Maturation and Limits CD8+ T Cell Terminal Differentiation Post-Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia Patients","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.11.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}